#United States #Class Action #Philadelphia #Berger Montague #Rocket Pharmaceuticals

Important Deadline Approaches for Rocket Pharmaceuticals Investors

Berger Montague PC, a well-known law firm based in Philadelphia, has issued a reminder to investors regarding an essential deadline concerning a securities class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This notice highlights the rights of investors who experienced losses related to the company's stock during a specific period.

Background of the Lawsuit

Rocket Pharmaceuticals specializes in developing gene therapies for rare and life-threatening diseases. Unfortunately, the company faced scrutiny after alleged non-disclosures regarding significant updates related to its RP-A501 clinical trial. In particular, the lawsuit claims that Rocket Pharmaceuticals did not reveal crucial safety-related information, including the use of an immunomodulatory agent and a subsequent fatal adverse event linked to the trial itself.

Following these events, which culminated in a clinical hold by the FDA, Rocket's stock price hit a devastating low. On May 28, 2025, the company publicly acknowledged the trial hold and the death of a patient, which led to a dramatic fall in share values—from $6.27 to $2.33 in a short period. These events have left many investors questioning the integrity of the company's disclosures and overall management.

Who Can Participate?

If you purchased Rocket Pharmaceuticals' stock between September 17, 2024, and May 26, 2025, you may be eligible to seek compensation due to the company's alleged misstatements and omissions. This period, known as the 'Class Period,' serves as the timeframe for potential claimants.

It's essential for investors to understand that the deadline to apply for lead plaintiff status in this class action lawsuit is August 11, 2025. Those interested in learning more about their rights or potential compensation should consult with legal professionals familiar with securities law to ensure their interests are adequately protected.

About Berger Montague

Founded in 1970, Berger Montague has developed a reputation as a pioneer in securities class action litigation. With offices across multiple states including Pennsylvania, Minnesota, and California, the firm has represented both individual and institutional investors over five decades, solidifying its standing as a leading advocate in courts throughout the United States.

Legal representatives from the firm express their commitment to guiding affected investors through the complexities of the lawsuit process and ensuring they are well-informed about their rights. Interested parties may reach out to:

• - Andrew Abramowitz, Senior Counsel

Phone: (215) 875-3015
Email: [email protected]

• - Caitlin Adorni

Phone: (267) 764-4865
Email: [email protected]

Conclusion

This situation emphasizes the importance of transparency and accountability in the pharmaceutical sector, especially when it comes to the safety and efficacy of clinical trials. As Rocket Pharmaceuticals navigates this legal challenge, investors should remain vigilant about their rights and options. For those impacted during the specified Class Period, taking timely action by seeking legal guidance is paramount to securing their interests in this unfolding matter.